User:Mr. Ibrahem/Efgartigimod alfa

Efgartigimod alfa, sold under the brand name Vyvgart, is a medication used to treat myasthenia gravis. Specifically it is used for generalized disease that has antibodies against the acetylcholine receptor. It is given by injection into a vein.

Common side effects include respiratory tract infections, headache, and urinary tract infections. Other side effect may include angioedema. It is an antibody fragment that binds to neonatal Fc receptor and prevents it from recycling immunoglobulin G (IgG). This decreases overall levels of IgG, including the abnormal acetylcholine receptor (AChR) antibodies in myasthenia gravis.

Efgartigimod alfa was approved for medical use in the United States in 2021 and Europe in 2022. In the United States it costs about 225,000 USD per year as of 2022. As of 2022 it is not commercially available in the United Kingdom.